Haemonetics Co. (NYSE:HAE - Get Free Report) EVP Anila Lingamneni sold 2,305 shares of Haemonetics stock in a transaction on Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the sale, the executive vice president now directly owns 12,295 shares of the company's stock, valued at approximately $1,168,025. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Haemonetics Price Performance
Haemonetics stock opened at $93.25 on Thursday. The stock has a 50-day moving average price of $83.59 and a two-hundred day moving average price of $82.81. Haemonetics Co. has a 12 month low of $70.74 and a 12 month high of $97.13. The company has a market capitalization of $4.74 billion, a PE ratio of 37.91, a P/E/G ratio of 2.23 and a beta of 0.34. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91.
Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.94 by $0.10. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The firm had revenue of $336.20 million for the quarter, compared to analyst estimates of $320.84 million. During the same period in the previous year, the firm posted $0.85 EPS. The company's revenue for the quarter was up 10.1% compared to the same quarter last year. Analysts expect that Haemonetics Co. will post 3.95 EPS for the current year.
Institutional Inflows and Outflows
The Best AI Stock to Own in the World Today is Trading for Just $25
From Banyan Hill Publishing | Ad
“Titan of Tech” Bets Big on Tiny AI Company
He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal…
But our research shows his latest investment could be his most successful venture yet.
See how you can invest alongside him
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Carmel Capital Partners LLC bought a new position in shares of Haemonetics during the third quarter worth about $30,000. TFO Wealth Partners LLC raised its holdings in Haemonetics by 29,450.0% during the 4th quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier's stock worth $51,000 after purchasing an additional 589 shares during the last quarter. Group One Trading L.P. acquired a new position in shares of Haemonetics in the 3rd quarter worth approximately $55,000. Parkside Financial Bank & Trust boosted its stake in shares of Haemonetics by 17.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier's stock valued at $90,000 after purchasing an additional 156 shares during the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Haemonetics during the first quarter worth $114,000. 99.67% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
HAE has been the topic of a number of recent research reports. Barrington Research restated an "outperform" rating and set a $105.00 price objective on shares of Haemonetics in a research note on Friday, April 12th. TheStreet downgraded shares of Haemonetics from a "b-" rating to a "c+" rating in a research note on Thursday, February 29th. Finally, StockNews.com cut shares of Haemonetics from a "buy" rating to a "hold" rating in a research report on Friday, March 22nd.
Check Out Our Latest Report on Haemonetics
About Haemonetics
(
Get Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
